226 related articles for article (PubMed ID: 26845288)
1. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with laronidase (Aldurazyme
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009354. PubMed ID: 31211405
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
[TBL] [Abstract][Full Text] [Related]
9. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Wraith JE; Beck M; Giugliani R; Harmatz P; Eng CM; Vellodi A; Martin R; Ramaswami U; Gucsavas-Calikoglu M; Vijayaraghavan S; Wendt S; Puga AC; Ulbrich B; Shinawi M; Cleary M; Piper D; Conway AM; Kimura A
Genet Med; 2006 Aug; 8(8):465-73. PubMed ID: 16912578
[TBL] [Abstract][Full Text] [Related]
10. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD009806. PubMed ID: 34533215
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
[TBL] [Abstract][Full Text] [Related]
15. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy for infantile-onset Pompe disease.
Chen M; Zhang L; Quan S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
[TBL] [Abstract][Full Text] [Related]
19. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.
Muenzer J; Beck M; Eng CM; Giugliani R; Harmatz P; Martin R; Ramaswami U; Vellodi A; Wraith JE; Cleary M; Gucsavas-Calikoglu M; Puga AC; Shinawi M; Ulbrich B; Vijayaraghavan S; Wendt S; Conway AM; Rossi A; Whiteman DA; Kimura A
Genet Med; 2011 Feb; 13(2):95-101. PubMed ID: 21150784
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of enzyme replacement therapy with idursulfase].
Gutiérrez-Solana LG
Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]